API | ferric derisomaltose

ferric derisomaltose (Monoferric) Report issue

Small molecule Approved ^FDA

AACT PubChem

Active Ingredient History

NOW

Ferric derisomaltose (FDI), sold under the brand name Monoferric among others, is a medication for the treatment of iron deficiency anemia (IDA) in adults who have intolerance to oral iron or have had unsatisfactory response to oral iron or who have non-hemodialysis dependent chronic kidney disease (NDD-CKD). Ferric derisomaltose is also known as ferric isomaltoside. It is widely accepted injectable iron treatment that causes fewer hypersensitivity reactions and anaphylactic shocks compared to other iron forms. It was approved for use in the United States in January 2020. It is given intravenously. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules:

iron isomaltoside 1000

ferric derisomaltose

More Chemistry

Pharmacology

Mechanisms of Action:
- Transferrin receptor protein 1 (Homo sapiens) ^UniProt
- Transferrin receptor protein 2 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Prescription Only
Delivery Methods: Missing data
Pro Drug: No

Drug Pricing (per unit)

Australia

$107.7047 - $215.4016

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

iron isomaltoside | isomaltoside

Organizations (64)

Research & Development (64)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (39)

Approved Indications (3)

Anemia

Anemia, Iron-Deficiency

Iron Deficiencies (approved 2020)

Experimental Indications - Clinical Trial Phases 1-4 (39)

Adult (Phase 4)

Anemia (Phase 4)

Anemia, Iron-Deficiency (Phase 4)

Aortic Stenosis, Subvalvular (Phase 4)

Bronchiectasis (Phase 3)

Chronic Kidney Disease-Mineral and Bone Disorder (Phase 1)

Colonic Neoplasms (Phase 2)

Colorectal Neoplasms (Phase 4)

Colorectal Surgery (Phase 4)

Deficiency Diseases (Phase 1)

Drug Misuse (Phase 4)

Esophageal Neoplasms (Phase 4)

General Surgery (Phase 4)

Genital Neoplasms, Female (Phase 3)

Heart Failure (Phase 4)

Heart Failure, Diastolic (Phase 4)

Heart Failure, Systolic (Phase 4)

Heart Transplantation (Phase 2/Phase 3)

Hematologic Diseases (Phase 1)

Hip Fractures (Phase 3)

Hypertrophy, Left Ventricular (Phase 4)

Infant, Low Birth Weight (Phase 4)

Inflammatory Bowel Diseases (Phase 4)

Iron Deficiencies (Phase 4)

Iron Metabolism Disorders (Phase 1)

Kidney Failure, Chronic (Phase 4)

Nasopharyngeal Carcinoma (Phase 2)

Neoplasms (Phase 3)

Obstetric Labor Complications (Early Phase 1)

Postoperative Complications (Phase 4)

Postpartum Hemorrhage (Phase 4)

Pregnancy (Phase 3)

Pregnancy Complications (Phase 4)

Renal Insufficiency, Chronic (Phase 3)

Restless Legs Syndrome (Phase 2)

Spinal Diseases (Phase 4)

Stomach Neoplasms (Phase 4)

Uterine Hemorrhage (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 69
# of Trial Organizations: 64

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue